8Pickerill KE, Paladino JA, Schentag JJ. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy, 2000,20:417-428.
9Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-aquired pneumonia.Diagnosis,assessment of severity, antimicrobial therapy, and provention. Am J Respir Crit Care Med, 2001,163:1730-1754.
10Niederman MS. Treatment of respiratory in fections with quinolones. In: An drole V, editor, The quinolones, 2nd edition. San Diego. CA: McGraw-Hill,1998.229-250.
3Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies [J]. Clin Infect Dis, 2001, 33(Suppl 3): 147-156.
4Clinical and Laboratory Standards lnstitute/NCCLS. Performance standards for antimicrobial susceptibility testing,Fifteenth informational supplement. CLSI/NCCLS document M100-S15 [M]. Wayne, Pennsylvania, Clinical and Laboratory Standards Institute, 2005, 25(1).
5Spiss H K, Kofler M, Hausdorfer H, et al. Streptococcus suis meningitis and neurophysiology of the acoustic system [J]. First case report from Austrial. Nervenarzt Aug. 1999, 70(8): 738-741.
